Feedback
Settings

Settings

Goto Application

2,936 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K36/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 294
1.WO/2022/061420FORMULATIONS COMPRISING BOTANICAL EXTRACTS
WO - 31.03.2022
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
 Appl.No PCT/AU2021/051126 Applicant APEX BIOTECH RESEARCH PTY LTD Inventor XIAO, Zhicheng
The invention relates generally to combinations and compositions comprising botanical extracts useful in the treatment or prevention of viral and bacterial infections. In particular, the invention relates to combinations and compositions comprising two or more compounds selected from andrographolide or a derivative, or pharmaceutically acceptable salt thereof, ursolic acid, or a pharmaceutically acceptable salt thereof, and piceid or a derivative, or pharmaceutically acceptable salt thereof and use of the combinations and compositions in the treatment or prevention of viral and bacterial infections.
2.20230372290FORMULATIONS COMPRISING BOTANICAL EXTRACTS
US - 23.11.2023
Int.Class A61K 31/365
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
 Appl.No 18246931 Applicant APEX BIOTECH RESEARCH PTY LTD Inventor Zhicheng XIAO

The invention relates generally to combinations and compositions comprising botanical extracts useful in the treatment or prevention of viral and bacterial infections. In particular, the invention relates to combinations and compositions comprising two or more compounds selected from andrographolide or a derivative, or pharmaceutically acceptable salt thereof, ursolic acid, or a pharmaceutically acceptable salt thereof, and piceid or a derivative, or pharmaceutically acceptable salt thereof and use of the combinations and compositions in the treatment or prevention of viral and bacterial infections.

3.2021106876FORMULATIONS COMPRISING BOTANICAL EXTRACTS
AU - 09.09.2021
Int.Class A61K 36/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
19Acanthaceae (Acanthus family)
 Appl.No 2021106876 Applicant Apex Biotech Research Pty Ltd Inventor He, Zhiyong
The application relates to antiviral compositions comprising andrographolide, ursolic acid, and piceid and their use in treatment of viral and bacterial infections (including COVID-19). Combinations of either andrographolide and ursolic acid, or andrographolide and piced are also disclosed. Alternatively, extracts from Andrographis paniculata(for andrographolide), Eriobotrya japonica (for ursolic acid), and Reynoutria japonica (piceid) are used. The combination can additionally comprise other antivirals including monoclonal antibodies.
4.3193951FORMULATIONS COMPRISING BOTANICAL EXTRACTS
CA - 31.03.2022
Int.Class A61K 31/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
 Appl.No 3193951 Applicant APEX BIOTECH RESEARCH PTY LTD Inventor XIAO, ZHICHENG
The invention relates generally to combinations and compositions comprising botanical extracts useful in the treatment or prevention of viral and bacterial infections. In particular, the invention relates to combinations and compositions comprising two or more compounds selected from andrographolide or a derivative, or pharmaceutically acceptable salt thereof, ursolic acid, or a pharmaceutically acceptable salt thereof, and piceid or a derivative, or pharmaceutically acceptable salt thereof and use of the combinations and compositions in the treatment or prevention of viral and bacterial infections.
5.20230173010Therapeutic treatment for the coronavirus disease COVID-19
US - 08.06.2023
Int.Class A61K 36/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
 Appl.No 18104030 Applicant Peter Joseph Mollick Inventor Peter Joseph Mollick

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after the patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of the herb thyme, also know as common thyme (Thymus vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

6.3179222THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19
CA - 07.10.2021
Int.Class A61K 36/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
 Appl.No 3179222 Applicant ,  Inventor MOLLICK, PETER J.
A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after the patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of the herb thyme, also know as common thyme (Thymus vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.
7.20220143121THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19
US - 12.05.2022
Int.Class A61K 36/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
 Appl.No 17602234 Applicant Peter Joseph Mollick Inventor Peter Joseph Mollick

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after the patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of the herb thyme, also know as common thyme (Thymus vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

8.20240075090THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19
US - 07.03.2024
Int.Class A61K 36/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
 Appl.No 18388823 Applicant Peter Joseph Mollick Inventor Peter Joseph Mollick

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an herb thyme also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

9.20240082336THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19
US - 14.03.2024
Int.Class A61K 36/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
 Appl.No 18388854 Applicant Peter Joseph Mollick Inventor Peter Joseph Mollick

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of a derivative or a combination of derivatives of an herb thyme also know as common thyme (Thymus vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

10.20250144163THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19
US - 08.05.2025
Int.Class A61K 36/53
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
 Appl.No 18387274 Applicant Peter Joseph Mollick Inventor Peter Joseph Mollick

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an extracted component or a combination of extracted components of an herb thyme leaf also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

# -